| Orthopedic Infections and Treatments | Lifetime | 49 | ES 1 | 99.58 |
| Surgical site infection prevention | Lifetime | 26 | ES 1 | 99.10 |
| COVID-19 Clinical Research Studies | Lifetime | 305 | ES 6 | 98.66 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 163 | ES 7 | 99.17 |
| Orthopaedic implants and arthroplasty | Lifetime | 281 | ES 2 | 99.09 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 150 | ES 8 | 99.11 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 248 | ES 15 | 98.64 |
| Infectious Diseases and Tuberculosis | Lifetime | 167 | ES 5 | 98.35 |
| Long-Term Effects of COVID-19 | Lifetime | 363 | ES 14 | 97.08 |
| Antibiotic Use and Resistance | Lifetime | 204 | ES 13 | 98.55 |
| Antibiotic Resistance in Bacteria | Lifetime | 545 | ES 28 | 98.39 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 438 | ES 16 | 98.28 |
| Neutropenia and Cancer Infections | Lifetime | 372 | ES 9 | 96.87 |
| Total Knee Arthroplasty Outcomes | Lifetime | 948 | ES 5 | 97.25 |
| Antifungal resistance and susceptibility | Lifetime | 901 | ES 48 | 95.99 |
| Neutropenia and Cancer Infections | 2021-2025 | 8 | ES 2 | 98.71 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 66 | ES 3 | 98.92 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 34 | ES 3 | 98.57 |
| Orthopedic Infections and Treatments | 2021-2025 | 46 | ES 1 | 98.74 |
| COVID-19 Clinical Research Studies | 2021-2025 | 345 | ES 6 | 98.32 |
| Antibiotic Use and Resistance | 2021-2025 | 69 | ES 3 | 98.03 |
| Surgical site infection prevention | 2021-2025 | 31 | ES 1 | 95.03 |
| Orthopaedic implants and arthroplasty | 2021-2025 | 177 | ES 1 | 97.24 |
| Long-Term Effects of COVID-19 | 2021-2025 | 684 | ES 45 | 94.55 |
| Antifungal resistance and susceptibility | 2021-2025 | 170 | ES 8 | 96.14 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 167 | ES 12 | 93.63 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 172 | ES 9 | 94.17 |
| Pneumonia and Respiratory Infections | 2021-2025 | 350 | ES 17 | 93.42 |
| Total Knee Arthroplasty Outcomes | 2021-2025 | 484 | ES 2 | 94.98 |
| COVID-19 and healthcare impacts | 2021-2025 | 901 | ES 28 | 89.30 |
| Fungal Infections and Studies | 2021-2025 | 340 | ES 12 | 91.20 |
| Cystic Fibrosis Research Advances | 2021-2025 | 710 | ES 31 | 85.92 |
| Infectious Diseases and Tuberculosis | 2021-2025 | 558 | ES 5 | 77.92 |
| Urinary Tract Infections Management | 2021-2025 | 876 | ES 30 | 76.57 |
| Infections and bacterial resistance | 2021-2025 | 118 | ES 5 | 74.04 |
